Hematological Toxicity of Combined Lutetium-177 Octreotate Radiopeptide-Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors Followed Long-Term Abstract #932

Introduction: Combination radiopeptide therapy (PRRT) with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential to increase myelotoxicity.
Aim(s): In a prospective clinical study of GEP NET patients treated with Lutetium-177 octreotate PRRT in combination with capecitabine and temozolomide, we characterized the incidence and degree of hematological toxicity.
Materials and methods: Well-differentiated progressive metastatic GEP-NETS in 65 patients were treated with four cycles of 7.8 GBq 177Lu-octreotate, 1650 mg/m2 capecitabine (n=28) and 1500 mg/m2 capecitabine with 200 mg/m2 temozolomide (n=37), and monitored for hematological toxicity over a 5-year period.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Murali Kesavan
Keywords: PRRT, GEP-NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2292 PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Wouter van der Zwan
#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#1469 Theragnostic Approach of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) – The Role of Nuclear Medicine (NM) in a Multidisciplinary Team
Introduction: NET pts are a clinical challenge requiring intervention of multiple medical specialties
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Teresa Lucio
Authors: Lucio T, Gaspar C, Cunha C, Roque R, ...
Keywords: PRRT, GEP-NET
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.